A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

被引：2

作者：

Christofyllakis, Konstantinos ^{[1
]}

Poeschel, Viola ^{[1
]}

Altmann, Bettina ^{[2
]}

Maurer, Stephanie ^{[1
]}

Lesan, Vadim ^{[1
]}

Bittenbring, Joerg ^{[1
]}

Kos, Igor Age ^{[1
]}

Kaddu-Mulindwa, Dominic ^{[1
]}

Abdi, Zanir ^{[1
]}

Fleser, Octavian ^{[1
]}

Altmeyer, Sarah ^{[1
]}

Neuendorff, Nina Rosa ^{[3
]}

Nickelsen, Maike ^{[4
]}

Held, Gerhard ^{[5
]}

Dreyling, Martin ^{[6
]}

Zettl, Florian ^{[7
]}

Buske, Christian ^{[8
]}

Lenz, Georg ^{[9
]}

Glass, Bertram ^{[10
]}

Chapuy, Bjoern ^{[11
]}

Schmitz, Norbert ^{[9
]}

Vassilakopoulos, Theodoros ^{[12
]}

Ott, German ^{[13
,14
]}

Siebert, Reiner ^{[15
,16
]}

Viardot, Andreas ^{[15
,16
]}

Scherer, Florian ^{[17
]}

Schmitz, Roland ^{[18
]}

Rosenwald, Andreas ^{[19
]}

Hellwig, Dirk ^{[20
]}

Loeffler, Markus ^{[2
]}

Stilgenbauer, Stephan ^{[21
]}

Thurner, Lorenz ^{[1
]}

Bewarder, Moritz ^{[1
]}

Ziepert, Marita ^{[2
]}

机构：

[1] Saarland Univ, Med Ctr, Dept Internal Med Oncol Hematol Clin Immunol & Rh, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany

[3] Univ Hosp Essen, Dept Haematol & Stem Cell Transplantat, Essen, Germany

[4] Onkol Lerchenfeld, Hamburg, Germany

[5] Westpfalz Klinikum, Dept Internal Med 1, Kaiserslautern, Germany

[6] LMU Univ Hosp, Dept Internal Med 3, Munich, Germany

[7] Klinikum Traunstein, Dept Hematol & Oncol, Traunstein, Germany

[8] Univ Hosp Ulm, Inst Expt Canc Res, Ulm, Germany

[9] Univ Hosp Muenster, Dept Med A Hematol Oncol & Pneumol, Munster, Germany

[10] Asklepios Klin St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[11] Charite, Med Ctr Berlin, Dept Hematol Oncol & Tumor Immunol, Campus Benjamin Franklin, Berlin, Germany

[12] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[13] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

[14] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[15] Ulm Univ, Inst Human Genet, Ulm, Germany

[16] Ulm Univ, Med Ctr, Ulm, Germany

[17] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[18] Univ Hosp Giessen, Inst Pathol Mol Cytol & Funct Genom, Giessen, Germany

[19] Julius Maximilians Univ Wurzburg, Inst Pathol, Wurzburg, Germany

[20] Univ Hosp Regensburg, Dept Nucl Med, Regensburg, Germany

[21] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[31] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoyle, Margaret
Paccagnella, Luisa
BLOOD, 2023, 142
[32] Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
Katz, Deborah A.
Chu, Michael P.
David, Kevin A.
Thieblemont, Catherine
Morley, Nicholas J.
Khan, Sharif S.
Chen, Yuqi
Kalabus, James
Morris, Joan
Anderson, Abraham
Avilion, Ariel A.
Gonzalez-Barca, Eva
BLOOD, 2019, 134
[33] A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma
Reddy, Nishitha M.
Simons, Rhea M.
Caldwell, Meghan E.
Chen, Heidi
Jagasia, Madan
Morgan, David S.
Park, Steven I.
Greer, John P.
Richards, Kristy L.
BLOOD, 2012, 120 (21)
[34] Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Delarue, Richard
Tilly, Herve
Mounier, Nicolas
Petrella, Tony
Salles, Gilles
Thieblemont, Catherine
Bologna, Serge
Ghesquieres, Herve
Hacini, Maya
Fruchart, Christophe
Ysebaert, Loic
Ferme, Christophe
Casasnovas, Olivier
Van Hoof, Achiel
Thyss, Antoine
Delmer, Alain
Fitoussi, Olivier
Molina, Thierry Jo
Haioun, Corinne
Bosly, Andre
LANCET ONCOLOGY, 2013, 14 (06): : 525 - 533
[35] Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Leonard, John P.
Kolibaba, Kathryn S.
Reeves, James A.
Tulpule, Anil
Flinn, Ian W.
Kolevska, Tatjana
Robles, Robert
Flowers, Christopher R.
Collins, Robert
DiBella, Nicholas J.
Papish, Steven W.
Venugopal, Parameswaran
Horodner, Andrew
Tabatabai, Amir
Hajdenberg, Julio
Park, Jaehong
Neuwirth, Rachel
Mulligan, George
Suryanarayan, Kaveri
Esseltine, Dixie-Lee
de Vos, Sven
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3538 - +
[36] Phase 2, open-label study of CUDC-907 with and without rituximab in patients with relapsed/refractory MYC-altered diffuse large B-cell lymphoma.
Landsburg, Daniel Jeffrey
Kelly, Kevin
Viner, Jaye
Wang, Jing
Gong, Lucy
Clancy, Myles Steven
Ma, Anna W.
Oki, Yasuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[37] Phase II study of durvalumab (anti-PD-L1 antibody) in combination with R-CHOP or lenalidomide plus R-CHOP in previously untreated, high-risk diffuse large B-cell lymphoma.
Nowakowski, Grzegorz S.
Kalakonda, Nagesh
Truemper, Lorenz
Everaus, Hele
Fustier, Pierre
Jaeger, Jonathan
Manzke, Oliver
Jager, Ulrich
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study
Rummel, Mathias J.
Kim, Tae Min
Aversa, Franco
Brugger, Wolfram
Capochiani, Enrico
Plenteda, Caterina
Re, Francesca
Task, Peter
McIntyre, Christine
Meier, Oliver
Osborne, Stuart
Smith, Rodney
Grigg, Andrew
BLOOD, 2017, 130
[39] Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Davies, Andrew J.
Caddy, Josh
McLaughlin, Katy
Wignall, Christopher
Waugh, Robert
Collins, Graham P.
Stanton, Louise
Saunders, Geoff N.
Cummin, Thomas
Schuh, Anna
Ardeshna, Kirit M.
McMillan, Andrew K.
Radford, John
Lewis, David John
Coleman, Adam R.
Griffiths, Gareth
Burton, Cathy
Barrans, Sharon
Johnson, Peter
BLOOD, 2022, 140 : 9478 - 9479
[40] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Giri, Pratyush
Patil, Sushrut
Ratnasingam, Sumita
Prince, H. Miles
Milliken, Samuel
Meijide, Javier Briones
Coyle, Luke
Van der Poel, Marjolein
Mulroney, Carolyn M.
Farooqui, Mohammed Z. H.
Wong, Hansen
Desai, Rajendra
Zugmaier, Gerhard
Mergen, Noemi
Cannell, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →